Michael Hornberger is Professor of Applied Dementia Research and Associate Dean of Innovation at Norwich Medical School at the University of East Anglia in the UK.He regularly meets patients with Alzheimer's disease as part of his research aimed at improving diagnosis, disease tracking and symptom management. Michael is originally from Germany and studied at the universities of Osnabruck and Vienna. He gravitated to England where he did his PhD at University College London before working at Cambridge University. He spent six years in Sydney, Australia, before returning to Cambridge. He finally arrived at UEA in November 2015. In his spare time, he listens to jazz.
TABLE OF CONTENTS
Preface
Prologue
Part I – Alois & Auguste (and a bit of Oskar)
Chapter 1 – Dr Hoffmann’s vision
Chapter 2 – Mrs Deter
Chapter 3 – Alois Alzheimer
Chapter 4 – Munich via Heidelberg
Chapter 5 – 1906
Chapter 6 – The Tübingen aftermath
Chapter 7 – Fischer’s disease
Chapter 8 – Alzheimer’s legacy
Part I – Summary
Part II – Memory and Space
Chapter 9 – ‘You are not my type’
Chapter 10 – The art of memory
Chapter 11 – ‘Secret’ memory techniques
Chapter 12 – ‘Attention!’”
Chapter 13 – ‘Enter the seahorse’
Chapter 14 – Encoding, storage, retrieval
Chapter 15 – ‘It’s all about access’
Chapter 16 – The imaginary Mrs A
Chapter 17 – Spatial Disorientation
Chapter 18 – ‘Lost in space’
Part II – Summary
Part III – Amyloid and Tau
Chapter 19 – Glorious proteins
Chapter 20 – Amyloid
Chapter 21 – Beta-amyloid formation
Chapter 22 – ‘Location, location, location… and timing’
Chapter 23 – Tau
Chapter 24 – ‘Who ordered all the phosphate?’
Chapter 25 – Tau ‘infection’
Chapter 26 – Amyloid versus Tau
Chapter 27 – The ‘emergence’ of the disease
Chapter 28 – Biomarker technology
Chapter 29 – Amyloid treatment approaches
Decreasing beta-amyloid production
Prevention of beta-amyloid accumulation
Increase of beta-amyloid removal
Chapter 30 – Tau treatment approaches
Decrease of overall tau
Decrease of tau phosphorylation
Decrease phosphorylated tau accumulation
Increase phosphorylated tau removal
Chapter 31 – Why have drug trials failed so far?
Phase I
Phase II
Phase III
Part III – Summary
Part IV – Genetics and lifestyle
Chapter 32 – Genetics 101
Chapter 33 – Familial Alzheimer’s disease
APP
PSEN
MAPT
Chapter 34 – ‘Modifiable’ risk genes
APOE
TREM2
Chapter 35 – A word on genetic testing
Chapter 36 – Non-modifiable lifestyle factors
Age
Education
Hearing loss
Chapter 37 – Modifiable lifestyle factors
Diabetes, hypertension and obesity
Physical activity
Diet and nutrition
Sleep
Other modifiable lifestyle risk factors
Part IV – Summary
Part V – Rarer forms of Alzheimer’s disease
Chapter 38 – Frontal variant Alzheimer’s disease
Chapter 39 – Posterior Cortical Atrophy
Chapter 40 – Logopenic variant primary progressive aphasia
Chapter 41 – Corticobasal syndrome
Chapter 42 – A final word on the rarer forms of Alzheimer’s disease
Part V – Summary
Epilogue
Further country specific links (English language)
Index
